{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T23:12:06Z","timestamp":1774998726961,"version":"3.50.1"},"reference-count":48,"publisher":"The Endocrine Society","issue":"3","license":[{"start":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T00:00:00Z","timestamp":1571616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Italian Ministry of Health","award":["GR-2011-02352160"],"award-info":[{"award-number":["GR-2011-02352160"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Intravenous aminobisphosphonates (N-BPs) can induce an acute phase reaction (APR) in up to 40% to 70% of first infusions, causing discomfort and often requiring intervention with analgesics or antipyretics.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Our aim was to explore the risk factors of APR in a large sample of patients with Paget\u2019s disease of bone (PDB) and to assess the possible preventive effects of vitamin D administration.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>An observational analysis was performed in 330 patients with PDB at the time of N-BP infusion. Then, an interventional study was performed in 66 patients with active, untreated PDB to evaluate if vitamin D administration (oral cholecalciferol 50 000 IU\/weekly for 8 weeks before infusion) may prevent APR.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In a retrospective study, APR occurred in 47.6% and 18.3% of naive or previously treated patients, respectively. Its prevalence progressively increased in relation to the severity of vitamin D deficiency, reaching 80.0% in patients with 25-hydroxyvitamin D (25OHD) levels below 10 ng\/mL (relative risk (RR) = 3.7; 95% confidence interval (CI) 2.8\u20134.7, P &amp;lt; .0001), even in cases previously treated with N-BPs. Moreover, APR occurred more frequently in patients who experienced a previous APR (RR = 2.8; 95% CI 1.5\u20135.2; P &amp;lt; .001) or in carriers of SQSTM1 mutation (RR = 2.3; 95% CI 1.3\u20134.2; P = .005). In the interventional study, vitamin D supplementation prevented APR in most cases, equivalent to a RR of 0.31 (95% CI 0.14\u20130.67; P &amp;lt; .005) with respect to prevalence rates of the observational cohort. A similar trend was observed concerning the occurrence of hypocalcemia.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The achievement of adequate 25OHD levels is recommended before N-BP infusion in order to minimize the risk of APR or hypocalcemia in PDB.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgz138","type":"journal-article","created":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T21:20:32Z","timestamp":1571692832000},"page":"e466-e476","source":"Crossref","is-referenced-by-count":16,"title":["Preventive Role of Vitamin D Supplementation for Acute Phase Reaction after Bisphosphonate Infusion in Paget\u2019s Disease"],"prefix":"10.1210","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3338-6339","authenticated-orcid":false,"given":"Daniela","family":"Merlotti","sequence":"first","affiliation":[{"name":"Division of Genetics and Cell Biology, San Raffaele Scientific Institute, Milan, Italy"},{"name":"Department of Medicine Surgery and Neurosciences, University of Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Rendina","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Federico II University Medical School, Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Muscariello","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Federico II University Medical School, Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tommaso","family":"Picchioni","sequence":"additional","affiliation":[{"name":"Department of Medicine Surgery and Neurosciences, University of Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Alessandri","sequence":"additional","affiliation":[{"name":"Department of Medicine Surgery and Neurosciences, University of Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianpaolo","family":"De Filippo","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Federico II University Medical School, Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Materozzi","sequence":"additional","affiliation":[{"name":"Department of Medicine Surgery and Neurosciences, University of Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Bianciardi","sequence":"additional","affiliation":[{"name":"Department of Medicine Surgery and Neurosciences, University of Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Beatrice","family":"Franci","sequence":"additional","affiliation":[{"name":"Department of Medicine Surgery and Neurosciences, University of Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Lucani","sequence":"additional","affiliation":[{"name":"Department of Medicine Surgery and Neurosciences, University of Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Cenci","sequence":"additional","affiliation":[{"name":"Division of Genetics and Cell Biology, San Raffaele Scientific Institute, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pasquale","family":"Strazzullo","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Federico II University Medical School, Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ranuccio","family":"Nuti","sequence":"additional","affiliation":[{"name":"Department of Medicine Surgery and Neurosciences, University of Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Gennari","sequence":"additional","affiliation":[{"name":"Department of Medicine Surgery and Neurosciences, University of Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2019,10,21]]},"reference":[{"key":"2021122102221328400_CIT0001","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/095952877706000105","article-title":"On a form of chronic inflammation of bones (Osteitis Deformans)","volume":"60","author":"Paget","year":"1877","journal-title":"Med Chir Trans."},{"key":"2021122102221328400_CIT0002","first-page":"1027","article-title":"Paget disease of bone.","volume-title":"Disorders of Bone and Mineral Metabolism","author":"Altman","year":"1991"},{"key":"2021122102221328400_CIT0003","doi-asserted-by":"crossref","first-page":"P3","DOI":"10.1359\/jbmr.06s201","article-title":"Update on the epidemiology of Paget\u2019s disease of bone","volume":"21","author":"Cooper","year":"2006","journal-title":"J Bone Miner Res."},{"issue":"3","key":"2021122102221328400_CIT0004","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1359\/jbmr.2002.17.3.465","article-title":"Incidence and natural history of Paget\u2019s disease of bone in England and Wales","volume":"17","author":"van Staa","year":"2002","journal-title":"J Bone Miner Res."},{"issue":"3","key":"2021122102221328400_CIT0005","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S8756-3282(02)00817-7","article-title":"Guidelines on the management of Paget\u2019s disease of bone","volume":"31","author":"Selby","year":"2002","journal-title":"Bone"},{"key":"2021122102221328400_CIT0006","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2147\/OARRR.S4504","article-title":"Current options for the treatment of Paget\u2019s disease of the bone","volume":"1","author":"Merlotti","year":"2009","journal-title":"Open Access Rheumatol."},{"issue":"9","key":"2021122102221328400_CIT0007","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.2174\/138955709788922683","article-title":"The use of intravenous aminobisphosphonates for the treatment of Paget\u2019s disease of bone","volume":"9","author":"Gennari","year":"2009","journal-title":"Mini Rev Med Chem."},{"issue":"2","key":"2021122102221328400_CIT0008","first-page":"235","article-title":"Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates","volume":"296","author":"Dunford","year":"2001","journal-title":"J Pharmacol Exp Ther."},{"issue":"5","key":"2021122102221328400_CIT0009","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.bone.2005.05.003","article-title":"Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite","volume":"38","author":"Nancollas","year":"2006","journal-title":"Bone."},{"issue":"5","key":"2021122102221328400_CIT0010","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.bone.2006.01.141","article-title":"Bisphosphonate actions: physical chemistry revisited","volume":"38","author":"Papapoulos","year":"2006","journal-title":"Bone."},{"issue":"6","key":"2021122102221328400_CIT0011","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/annonc\/mdj105","article-title":"Management of the adverse effects associated with intravenous bisphosphonates","volume":"17","author":"Tanvetyanon","year":"2006","journal-title":"Ann Oncol."},{"issue":"8","key":"2021122102221328400_CIT0012","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00198-006-0322-8","article-title":"A systematic review of persistence and compliance with bisphosphonates for osteoporosis","volume":"18","author":"Cramer","year":"2007","journal-title":"Osteoporos Int."},{"issue":"2","key":"2021122102221328400_CIT0013","first-page":"103","article-title":"A Method for retrieval of adverse event terms in clinical trial databases using standardised MedDRA queries","volume":"30","author":"Breder","year":"2016","journal-title":"Pharmaceut Med."},{"issue":"1","key":"2021122102221328400_CIT0014","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/bcp.12944","article-title":"Adverse drug event reporting systems: a systematic review","volume":"82","author":"Bailey","year":"2016","journal-title":"Br J Clin Pharmacol."},{"issue":"9","key":"2021122102221328400_CIT0015","doi-asserted-by":"crossref","first-page":"4380","DOI":"10.1210\/jc.2010-0597","article-title":"Characterization of and risk factors for the acute-phase response after zoledronic acid","volume":"95","author":"Reid","year":"2010","journal-title":"J Clin Endocrinol Metab."},{"issue":"9","key":"2021122102221328400_CIT0016","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1007\/s00198-011-1881-x","article-title":"Persistence with intravenous zoledronate in elderly patients with osteoporosis","volume":"23","author":"Lee","year":"2012","journal-title":"Osteoporos Int."},{"issue":"6","key":"2021122102221328400_CIT0017","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/BF02556671","article-title":"The acute-phase response after bisphosphonate administration","volume":"41","author":"Adami","year":"1987","journal-title":"Calcif Tissue Int."},{"issue":"5","key":"2021122102221328400_CIT0018","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s002239900353","article-title":"An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates","volume":"61","author":"Thi\u00e9baud","year":"1997","journal-title":"Calcif Tissue Int."},{"issue":"11","key":"2021122102221328400_CIT0019","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1089\/107999003322558782","article-title":"Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6","volume":"23","author":"Dicuonzo","year":"2003","journal-title":"J Interferon Cytokine Res."},{"issue":"2","key":"2021122102221328400_CIT0020","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2141.2008.07435.x","article-title":"Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP\/DMAPP","volume":"144","author":"Roelofs","year":"2009","journal-title":"Br J Haematol."},{"issue":"2","key":"2021122102221328400_CIT0021","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1084\/jem.20021500","article-title":"Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells","volume":"197","author":"Gober","year":"2003","journal-title":"J Exp Med."},{"issue":"2","key":"2021122102221328400_CIT0022","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1359\/JBMR.0301230","article-title":"Statins prevent bisphosphonate-induced gamma,delta-T-cell proliferation and activation in vitro","volume":"19","author":"Thompson","year":"2004","journal-title":"J Bone Miner Res."},{"issue":"2","key":"2021122102221328400_CIT0023","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1021\/jm0303709","article-title":"Quantitative structure-activity relationships for gammadelta T cell activation by bisphosphonates","volume":"47","author":"Sanders","year":"2004","journal-title":"J Med Chem."},{"issue":"1","key":"2021122102221328400_CIT0024","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2249.2005.02665.x","article-title":"The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood \u03b3\u03b4 T cells in response to aminobisphosphonates is inhibited by statins","volume":"139","author":"Hewitt","year":"2005","journal-title":"Clin Exp Immunol."},{"issue":"5","key":"2021122102221328400_CIT0025","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s00223-011-9468-2","article-title":"No effect of rosuvastatin in the zoledronate-induced acute-phase response","volume":"88","author":"Makras","year":"2011","journal-title":"Calcif Tissue Int."},{"issue":"1","key":"2021122102221328400_CIT0026","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.bone.2010.10.177","article-title":"Fluvastatin does not prevent the acute-phase response to intravenous zoledronic acid in post-menopausal women","volume":"49","author":"Thompson","year":"2011","journal-title":"Bone."},{"issue":"8","key":"2021122102221328400_CIT0027","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1007\/s00198-010-1448-2","article-title":"Effect of acetaminophen and fluvastatin on post-dose symptoms following infusion of zoledronic acid","volume":"22","author":"Silverman","year":"2011","journal-title":"Osteoporos Int."},{"issue":"3","key":"2021122102221328400_CIT0028","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/jbmr.1797","article-title":"Monocytes and \u03b3\u03b4 T cells control the acute-phase response to intravenous zoledronate: insights from a phase IV safety trial","volume":"28","author":"Welton","year":"2013","journal-title":"J Bone Miner Res."},{"issue":"1","key":"2021122102221328400_CIT0029","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/jbmr.521","article-title":"Circulating \u03b3\u03b4 T cells and the risk of acute-phase response after zoledronic acid administration","volume":"27","author":"Rossini","year":"2012","journal-title":"J Bone Miner Res."},{"issue":"6","key":"2021122102221328400_CIT0030","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00223-012-9647-9","article-title":"Long-term effects of amino-bisphosphonates on circulating \u03b3\u03b4 T cells","volume":"91","author":"Rossini","year":"2012","journal-title":"Calcif Tissue Int."},{"issue":"3","key":"2021122102221328400_CIT0031","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1359\/jbmr.090819","article-title":"Serum 25-hydroxyvitamin D levels modulate the acute-phase response associated with the first nitrogen-containing bisphosphonate infusion","volume":"25","author":"Bertoldo","year":"2010","journal-title":"J Bone Miner Res."},{"issue":"1","key":"2021122102221328400_CIT0032","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1172\/JCI115584","article-title":"Interleukin 6. A potential autocrine\/paracrine factor in Paget\u2019s disease of bone","volume":"89","author":"Roodman","year":"1992","journal-title":"J Clin Invest."},{"issue":"8","key":"2021122102221328400_CIT0033","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1097\/j.pain.0000000000001260","article-title":"Interleukin-6 trans-signaling and pathological low back pain in patients with Paget disease of bone","volume":"159","author":"Rendina","year":"2018","journal-title":"Pain."},{"issue":"10","key":"2021122102221328400_CIT0034","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1359\/jbmr.070704","article-title":"Comparison of different intravenous bisphosphonate regimens for Paget\u2019s disease of bone","volume":"22","author":"Merlotti","year":"2007","journal-title":"J Bone Miner Res."},{"issue":"3","key":"2021122102221328400_CIT0035","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/jbmr.237","article-title":"Comparison of intravenous and intramuscular neridronate regimens for the treatment of Paget disease of bone","volume":"26","author":"Merlotti","year":"2011","journal-title":"J Bone Miner Res."},{"key":"2021122102221328400_CIT0036","volume-title":"2003 Medical Dictionary for Regulatory Activities (MedDRA)"},{"issue":"3","key":"2021122102221328400_CIT0037","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1056\/NEJMra070553","article-title":"Vitamin D deficiency","volume":"357","author":"Holick","year":"2007","journal-title":"N Engl J Med."},{"issue":"7","key":"2021122102221328400_CIT0038","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1210\/jc.2011-0385","article-title":"Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline","volume":"96","author":"Holick","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"key":"2021122102221328400_CIT0039"},{"issue":"1","key":"2021122102221328400_CIT0040","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1210\/jc.2010-2704","article-title":"The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know","volume":"96","author":"Ross","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"issue":"18","key":"2021122102221328400_CIT0041","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med."},{"issue":"9","key":"2021122102221328400_CIT0042","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1002\/jbmr.438","article-title":"A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years","volume":"26","author":"Reid","year":"2011","journal-title":"J Bone Miner Res."},{"issue":"2","key":"2021122102221328400_CIT0043","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/jbmr.290","article-title":"Serum 25-hydroxyvitamin D level and acute-phase reaction following initial intravenous bisphosphonate","volume":"26","author":"Srivastava","year":"2011","journal-title":"J Bone Miner Res."},{"issue":"5","key":"2021122102221328400_CIT0044","doi-asserted-by":"crossref","first-page":"405","DOI":"10.4158\/EP161638.OR","article-title":"Acute phase reactions after zoledronic acid infusion: protective role of 25-hydroxyvitamin D and previous oral bisphosphonate therapy","volume":"24","author":"Crotti","year":"2018","journal-title":"Endocr Pract."},{"issue":"1","key":"2021122102221328400_CIT0045","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00198-012-2117-4","article-title":"The impact of dietary calcium intake and vitamin D status on the effects of zoledronate","volume":"24","author":"Bourke","year":"2013","journal-title":"Osteoporos Int."},{"issue":"6","key":"2021122102221328400_CIT0046","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1002\/jbmr.31","article-title":"SQSTM1 gene analysis and gene-environment interaction in Paget\u2019s disease of bone","volume":"25","author":"Gennari","year":"2010","journal-title":"J Bone Miner Res."},{"issue":"11","key":"2021122102221328400_CIT0047","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/jbmr.132","article-title":"Mutations of SQSTM1 are associated with severity and clinical outcome in Paget disease of bone","volume":"25","author":"Visconti","year":"2010","journal-title":"J Bone Miner Res."},{"issue":"6","key":"2021122102221328400_CIT0048","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1002\/jbmr.5650100617","article-title":"Interleukin-6 and the acute phase response during treatment of patients with Paget\u2019s disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate","volume":"10","author":"Schweitzer","year":"1995","journal-title":"J Bone Miner Res."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgz138\/30254571\/dgz138.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/105\/3\/e466\/41823721\/jcem_105_3_e466.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/105\/3\/e466\/41823721\/jcem_105_3_e466.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T02:23:29Z","timestamp":1640053409000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/105\/3\/e466\/5601913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,21]]},"references-count":48,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,10,21]]},"published-print":{"date-parts":[[2020,3,1]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgz138","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,3]]},"published":{"date-parts":[[2019,10,21]]}}}